Role of Silver Nitrate Spray for Skin Wound Care in Patients with Toxic Epidermal Necrolysis: Our Experience in 4 Patients
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
SJS | Stevens–Johnson Syndrome |
TEN | Toxic epidermal necrolysis |
SCARs | Severe cutaneous adverse reactions |
AGEP | Acute generalized exanthematous pustulosis |
GBFDE | Generalized bullous fixed drug eruption |
HIV | Human immunodeficiency virus |
HLA | Human leukocyte antigens |
BSA | Body surface area |
NSAIDs | Non-steroidal anti-inflammatory drugs |
References
- Schneider, J.A.; Cohen, P.R. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures. Adv. Ther. 2017, 34, 1235–1244. [Google Scholar] [CrossRef]
- Hsu, D.Y.; Brieva, J.; Silverberg, N.B.; Silverberg, J.I. Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. J. Investig. Dermatol. 2016, 136, 1387–1397. [Google Scholar] [CrossRef] [PubMed]
- Lee, E.Y.; Knox, C.; Phillips, E.J. Worldwide Prevalence of Antibiotic-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis. JAMA Dermatol. 2023, 159, 384–392. [Google Scholar] [CrossRef] [PubMed]
- Chantaphakul, H.; Sanon, T.; Klaewsongkram, J. Clinical characteristics and treatment outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis. Exp. Ther. Med. 2015, 10, 519–524. [Google Scholar] [CrossRef] [PubMed]
- Duong, T.A.; Valeyrie-Allanore, L.; Wolkenstein, P.; Chosidow, O. Severe cutaneous adverse reactions to drugs. Lancet 2017, 390, 1996–2011. [Google Scholar] [CrossRef]
- Cho, Y.T.; Chu, C.Y. Treatments for Severe Cutaneous Adverse Reactions. J. Immunol. Res. 2017, 2017, 1503709. [Google Scholar] [CrossRef] [PubMed]
- Pisano, C.; Brown, M.; Jambusaria, A. A comparison of international treatment guidelines for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Int. J. Dermatol. 2023, 62, 397–403. [Google Scholar] [CrossRef]
- Seminario-Vidal, L.; Kroshinsky, D.; Malachowski, S.J.; Sun, J.; Markova, A.; Beachkofsky, T.M.; Kaffenberger, B.H.; Ergen, E.N.; Mauskar, M.; Bridges, A.; et al. Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. J. Am. Acad. Dermatol. 2020, 82, 1553–1567. [Google Scholar] [CrossRef] [PubMed]
- Zimmermann, S.; Sekula, P.; Venhoff, M.; Motschall, E.; Knaus, J.; Schumacher, M.; Mockenhaupt, M. Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis. JAMA Dermatol. 2017, 153, 514–522. [Google Scholar] [CrossRef] [PubMed]
- Ng, Q.X.; De Deyn, M.L.Z.Q.; Venkatanarayanan, N.; Ho, C.Y.X.; Yeo, W.S. A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis. J. Inflamm. Res. 2018, 11, 135–142. [Google Scholar] [CrossRef] [PubMed]
- González-Herrada, C.; Rodríguez-Martín, S.; Cachafeiro, L.; Lerma, V.; Gonzalez, O.; Lorente, J.A.; Rodríguez-Miguel, A.; González-Ramos, J.; Roustan, G.; Ramírez, E.; et al. Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: Evidence from three different approaches. J. Investig. Dermatol. 2017, 137, 2092–2100. [Google Scholar] [CrossRef] [PubMed]
- Tian, C.C.; Ai, X.C.; Ma, J.C.; Hu, F.Q.; Liu, X.T.; Luo, Y.J.; Tan, G.Z.; Zhang, J.M.; Li, X.Q.; Guo, Q.; et al. Etanercept treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann. Allergy Asthma Immunol. 2022, 129, 360–365.e1. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.; Lu, C.W.; Chen, C.B.; Chen, W.T.; Cheng, B. Evaluation of Combination Therapy with Etanercept and Systemic Corticosteroids for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Observational Study. J. Allergy Clin. Immunol. Pract. 2022, 10, 1295–1304.e6. [Google Scholar] [CrossRef] [PubMed]
- Kherlopian, A.; Mewton, E.; Fong, G.; Fischer, G. Highlighting adalimumab as a treatment option for systemic treatment of toxic epidermal necrolysis: A case series from a tertiary specialised burns centre. Australas. J. Dermatol. 2022, 63, 497–504. [Google Scholar] [CrossRef] [PubMed]
- Jaller, J.A.; McLellan, B.N.; Balagula, Y. Wound management in Stevens-Johnson Syndrome and toxic epidermal necrolysis. Curr. Dermatol. Rep. 2020, 9, 58–72. [Google Scholar] [CrossRef]
- Smith, S.D.; Dodds, A.; Dixit, S.; Cooper, A. Role of nanocrystalline silver dressings in the management of toxic epidermal necrolysis (TEN) and TEN/Stevens-Johnson syndrome overlap. Australas. J. Dermatol. 2015, 56, 298–302. [Google Scholar] [CrossRef] [PubMed]
- Woodmansey, E.J.; Roberts, C.D. Appropriate use of dressings containing nanocrystalline silver to support antimicrobial stewardship in wounds. Int. Wound. J. 2018, 15, 1025–1032. [Google Scholar] [CrossRef]
- Choi, H.; Castillo, B.; Seminario-Vidal, L. Silver absorption in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis treated with silver-impregnated dressings. A case series. Int. Wound. J. 2018, 15, 1049–1051. [Google Scholar] [CrossRef]
- Endorf, F.W.; Cancio, L.C.; Gibran, N.S. Toxic epidermal necrolysis clinical guidelines. J. Burn. Care Res. 2008, 29, 706–712. [Google Scholar] [CrossRef]
- Ingen-Housz-Oro, S.; Duong, T.A.; Bensaid, B.; Bellon, N.; de Prost, N.; Lu, D.; Lebrun-Vignes, B.; Gueudry, J.; Bequignon, E.; Zaghbib, K.; et al. Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de diagnostic et de soins). Orphanet. J. Rare Dis. 2018, 13, 56. [Google Scholar] [CrossRef]
- Nizamoglu, M.; Ward, J.A.; Frew, Q.; Gerrish, H.; Martin, N.; Shaw, A. Improving mortality outcomes of Stevens Johnson syndrome/toxic epidermal necrolysis: A regional burns centre experience. Burns 2018, 44, 603–611. [Google Scholar] [CrossRef] [PubMed]
- Haravu, P.N.; Gottlieb, L.J.; Vrouwe, S.Q. Antishear Therapy for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Follow-up Study. J. Burn. Care Res. 2021, 42, 1152–1161. [Google Scholar] [CrossRef] [PubMed]
- Liao, Z.J.; Huan, J.N.; Lv, G.Z.; Shou, Y.M.; Wang, Z.Y. Multi-center clinical study of the effect of silver nitrate ointment on the partial-thickness burn wounds. Zhonghua Shao Shang Za Zhi 2006, 22, 359–361. [Google Scholar] [PubMed]
- Lansdown, A.B.; Williams, A. How safe is silver in wound care? J. Wound. Care 2004, 13, 131–136. [Google Scholar] [CrossRef]
- Tatu, A.L.; Ardeleanu, V.; Elisei, A.M.; Dumitriu Buzia, O.; Miulescu, M.; Nwabudike, L.C. Undesirable effects of some topical antiseptics chemical, pharmacological and dermatological aspects. Rev. Chim. 2019, 70, 2276–2281. [Google Scholar] [CrossRef]
Classification | Percent of Body Surface Area with Epidermal Detachment |
---|---|
SJS | <10% |
SJS/TEN overlap | 10–30% |
TEN | >30% |
Gender | Female | Female | Female | Male |
---|---|---|---|---|
Age | 3 y/o | 51 y/o | 57 y/o | 28 y/o |
Latency | 2 weeks | 3.2 weeks | 2.4 weeks | 2.2 weeks |
Culprit drug | Ibuprofen | Carbamazepine | Moxifloxacin | Carbamazepine |
Systemic therapy | Dexamethasone | Dexamethasone + CyA | Dexamethasone + CyA | Dexamethasone + IVIG |
HIV infection | - | - | - | - |
Comorbidities | None | TN | COPD | Epilepsy |
SCORTEN | 2 | 3 | 3 | 3 |
Total BSA affected/detachment % | 80/40 | 90/50 | 80/50 | 90/40 |
Prodromal period | + | + | + | + |
Mucosal involvement | + | + | + | + |
Genital involvement | + | + | + | + |
Ocular involvement | + | + | + | + |
Rash | + | + | + | + |
Hospital stay | 7 days | 15 days | 7 days | 21 days |
Laboratory findings | - | - | - | - |
Parameter | Value for SCORTEN (1 Point) |
---|---|
Age | >40 years |
Cancer | Yes |
Percentage of skin detachment | >10% |
Pulse rate | >120/min |
Serum bicarbonate | <20 meq/L |
Blood urea nitrogen | >28 mg/dL |
Glycemia | >252 mg/dL |
Total score | Estimated risk of death in the acute phase |
0–1 | 3% |
2 | 12% |
3 | 35% |
4 | 58% |
>5 | 90% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Martinez, J.D.; Cardenas, J.A.; Soria, M.; Saenz, L.M.; Estrada, K.; Delgado, S.M.; Ionescu, M.-A.; Busila, C.; Tatu, A.L. Role of Silver Nitrate Spray for Skin Wound Care in Patients with Toxic Epidermal Necrolysis: Our Experience in 4 Patients. Life 2023, 13, 2341. https://doi.org/10.3390/life13122341
Martinez JD, Cardenas JA, Soria M, Saenz LM, Estrada K, Delgado SM, Ionescu M-A, Busila C, Tatu AL. Role of Silver Nitrate Spray for Skin Wound Care in Patients with Toxic Epidermal Necrolysis: Our Experience in 4 Patients. Life. 2023; 13(12):2341. https://doi.org/10.3390/life13122341
Chicago/Turabian StyleMartinez, Jose Dario, Jesus Alberto Cardenas, Manuel Soria, Luis Manuel Saenz, Kattya Estrada, Sergio Maximo Delgado, Marius-Anton Ionescu, Camelia Busila, and Alin Laurentiu Tatu. 2023. "Role of Silver Nitrate Spray for Skin Wound Care in Patients with Toxic Epidermal Necrolysis: Our Experience in 4 Patients" Life 13, no. 12: 2341. https://doi.org/10.3390/life13122341
APA StyleMartinez, J. D., Cardenas, J. A., Soria, M., Saenz, L. M., Estrada, K., Delgado, S. M., Ionescu, M.-A., Busila, C., & Tatu, A. L. (2023). Role of Silver Nitrate Spray for Skin Wound Care in Patients with Toxic Epidermal Necrolysis: Our Experience in 4 Patients. Life, 13(12), 2341. https://doi.org/10.3390/life13122341